EHA 2021 | Update on the ICARIA-MM trial

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the latest data from a number of Phase III trials investigating the use of isatuximab, a CD38-targeting monoclonal antibody, combined with immunomodulatory/proteasome-targeting agents for the treatment of relapsed/refractory (R/R) multiple myeloma. Dr Richardson shares updated data from the Phase III ICARIA-MM trial (NCT02990338), currently investigating the use of isatuximab plus pomalidomide and low-dose dexamethasone compared to pomalidomide and low-dose dexamethasone in R/R multiple myeloma. The trial demonstrated significantly improved outcomes for patients treated with isatuximab plus pomalidomide and low-dose dexamethasone, with a median progression-free survival of 17.5 months compared to 13 months. Dr Richardson also speaks on the longer-term outcomes such as overall survival (OS) and time to next treatment (TTNT), suggesting a favorable efficacy profile for its use in the R/R domain. Dr Richardson compares this data with results from the Phase III APOLLO trial (NCT03180736), demonstrating similar efficacy patterns. Additionally, Dr Richardson shares data from the Phase III IKEMA trial (NCT03275285) which is investigating the combination of isatuximab plus carfilzomib and dexamethasone, again achieving significant PFS. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.